Zabielska-Koczywąs Katarzyna, Wojtalewicz Anna, Lechowski Roman
Department of Small Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, 02-776, Warsaw, Poland.
Acta Vet Scand. 2017 Jul 17;59(1):47. doi: 10.1186/s13028-017-0315-y.
Feline injection-site sarcomas (FISS) are malignant skin tumours of mesenchymal origin, the treatment of which is a challenge for veterinary surgeons. The role of surgery, radiotherapy and chemotherapy in FISS treatment has been studied, and a correlation between "clean" surgical margins and disease-free survival has been shown. In addition, clean surgical margins are one of the most important factors for achieving a low recurrence rate. The most effective method of FISS treatment includes combining radical surgery with pre- or postoperative radiotherapy. Chemotherapy may be used as a palliative method of treatment or may be considered an adjunctive therapy for surgery and radiotherapy. In cats with FISS without metastasis, the use of immunostimulant treatment with Oncept IL-2, intended as a complementary immunotherapy in association with surgery and brachytherapy, may also be considered to reduce the risk of relapse and increase the time to relapse. Additionally, this review focuses on recent advances in FISS treatment, including the use of novel compounds, such as doxorubicin conjugated to glutathione-stabilized gold nanoparticles, liposomal doxorubicin or tyrosine kinase inhibitors.
猫注射部位肉瘤（FISS）是间充质起源的恶性皮肤肿瘤，其治疗对兽医来说是一项挑战。手术、放疗和化疗在FISS治疗中的作用已得到研究，并且已显示“切缘干净”与无病生存期之间存在相关性。此外，切缘干净是实现低复发率的最重要因素之一。FISS最有效的治疗方法包括根治性手术与术前或术后放疗相结合。化疗可作为一种姑息性治疗方法，也可被视为手术和放疗的辅助治疗。在没有转移的FISS猫中，使用Oncept IL-2进行免疫刺激治疗，作为与手术和近距离放疗联合的辅助免疫疗法，也可考虑用于降低复发风险并延长复发时间。此外，本综述重点关注FISS治疗的最新进展，包括使用新型化合物，如与谷胱甘肽稳定的金纳米颗粒偶联的阿霉素、脂质体阿霉素或酪氨酸激酶抑制剂。
